Vivalis Signs New Eb66 Research License With MYMETICS Corporation
Published: Sep 28, 2010
NANTES, FRANCE--(Marketwire - September 28, 2010) -
companynewsgroup Home Page
Terms of the agreement were not disclosed.
"We are very pleased to have another organization evaluating our EB66® cell line. This agreement brings the number of worldwide, new research and commercial licenses to the EB66® cell line up to four in 2010. We also continue to engage in advanced discussions with many organizations, both for vaccine and protein production, and are confident that 2010 will continue to reinforce our position as a provider of novel cell-based technologies to the biopharmaceutical industry," said Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS.
Next Financial Press Release
October 20, 2010: Third Quarter Revenues for 2010 (after NYSE Euronext market close)
About The EB66® Cell Line
The EB66® cell line, derived from avian embryonic stem cells, presents unique industrial and regulatory characteristics, such as long-term genetic stability, immortality and cell growth up to high cell densities in suspension using serum-free media ( > 40 million cells/mL).
EB66® cells replicate a wide range of human and animal viruses and are currently used for the production of investigational viral vaccines by many major vaccine developers.
A Biologics Master File (BMF) for the EB66® cell line with the U.S. Food and Drug Administration (FDA) was filed on June 27, 2008 and is updated annually.
EB66® cells are also easily engineered to express recombinant proteins of interest ( > 1.0 g/l). Monoclonal antibodies produced in EB66® cells have a human-like glycosylation profile with the additional benefits of reduced fucose content, naturally. This latter characteristic provides increased cytotoxic activity (ADCC) to antibodies, which may be useful in the treatment of cancer and infectious disease.
About VIVALIS (www.vivalis.com)
VIVALIS (Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. VIVALIS' expertise and intellectual property are leveraged in three main areas:
EB66® Cell Line
VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP's, and recombinant proteins (with a focus on monoclonal antibodies having enhanced cytotoxic activity). Through these programs VIVALIS receives upfront, clinical, and milestone payments along with royalties on licensees net sales.
Humalex® Human Antibody Discovery Platform
Customized solutions for the discovery, development, and production of fully human monoclonal antibodies is now offered by VIVALIS. Through these programs VIVALIS receives upfront, clinical, and milestone payments along with royalties on licensees net sales.
VIVALIS performs discovery and early stage development of small molecules identified with VIVALIS' proprietary 3D-Screen platform, which identifies target protein conformational modulators. VIVALIS is also building a portfolio of proprietary products for the treatment of hepatitis-C infection using this platform.
Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud Group (ca. 1,500 employees), a world-wide leader in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Merck, CSL, Kaketsuken, Merial, Intervet, SAFC Biosciences. VIVALIS is a member of both the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters.
+-------------------------+-+ |VIVALIS | | +-------------------------+-+ |Listed on Euronext Paris | | | Compartment C of NYSE | | |Euronext | | +-------------------------+-+ |Reuters: VLS.PA | | |Bloomberg: VLS FP | | +-------------------------+-+ |Included in NYSE | | |Euronexts SBF 250, CAC | | |Small 90 and Next Biotech| | |indices | | +-------------------------+-+ +-------------------------+-+This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's document de référence, changes in economic conditions, the financial markets or the markets in which the company operates.
Franck Grimaud, CEO
Email: Email Contact
Financial communications agency
Steve Grobet / Pierre Laurent
Tel.: +33 (0) 1 44 71 94 91
Email: Email Contact
This information is provided by HUGIN